Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Influenza virus vaccine quadrivalent - Sinovac Biotech

Drug Profile

Influenza virus vaccine quadrivalent - Sinovac Biotech

Latest Information Update: 27 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sinovac Biotech
  • Class Influenza virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preregistration Influenza virus infections

Most Recent Events

  • 15 Aug 2019 Sinovac intends to launch influenza virus vaccine quadrivalent in China for Influenza virus infections in 2020
  • 05 Mar 2019 Sinovac Biotech completes a phase III trial in Influenza virus infections (Prevention, In infants, In children) in China (NCT03859141)
  • 28 Feb 2019 Preregistration for Influenza virus infections (In adolescents, In children, In the elderly, In infants, Prevention, In adults) in China prior to April 2019
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top